biOasis Technologies Inc
XTSX:BTI
Intrinsic Value
biOasis Technologies, Inc. operates as a biopharmaceutical company. [ Read More ]
The intrinsic value of one
BTI
stock under the Base Case scenario is
0.03
CAD.
Compared to the current market price of 0.01 CAD,
biOasis Technologies Inc
is
Undervalued by 61%.
biOasis Technologies Inc's market capitalization is 397.1k CAD.
BTI stock price is 0.01 CAD.
BTI stock price (0.01 CAD) is 61% less than its Intrinsic Value (0.03 CAD).
BTI. Open DCF Valuation
BTI.
BTI's Revenue has grown by an exceptional 614% over the past 12 months.
BTI's ROE (Return on Equity) has significantly increased in the last 3 years from -67% to 135%.
BTI's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -26% to 581%.
BTI has negative Operating Income for the last twelve months.
BTI has negative Net Income for the last twelve months.
BTI's ROE (Return on Equity) for the past 12 months is very high and is equal to 135%.
BTI's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 581%.
BTI has positive Net Debt. This means that the company has more debt (714k CAD) than cash and short-term investments (157k CAD).
BTI's long-term liabilties (4m CAD) exceed its long-term assets (2m CAD).
BTI has negative Free Cash Flow for the last twelve months.
BTI's short-term liabilties (4m CAD) exceed its short-term assets (384k CAD).
BTI has very high three-year average ROE (Return on Equity): 273%. The company is very efficient at transforming stockholders' equity into net income.
BTI has very high three-year average ROIC (Return on Invested Capital): 329%. The company is very efficient at using invested capital to generate operating income.
BTI's D/E (Debt to Equity) is very low and is equal to -0.26.
BTI's Altman Z-Score is very low and is equal to -41.11.
BTI doesn't generate enough operating income (-3m CAD) to safely cover interest payments on its debt (2k CAD).
Valuation Backtest
biOasis Technologies Inc
Run backtest to discover the historical profit from buying and selling
BTI
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
biOasis Technologies Inc
Balance Sheet Decomposition
biOasis Technologies Inc
| Current Assets | 383.6k |
| Cash & Short-Term Investments | 156.5k |
| Receivables | 13.9k |
| Other Current Assets | 213.2k |
| Non-Current Assets | 1.4m |
| PP&E | 40 |
| Intangibles | 1.4m |
| Other Non-Current Assets | 10 |
| Current Liabilities | 3.6m |
| Accounts Payable | 1.9m |
| Other Current Liabilities | 1.7m |
| Non-Current Liabilities | 856.6k |
| Long-Term Debt | 713.6k |
| Other Non-Current Liabilities | 143k |
Earnings Waterfall
biOasis Technologies Inc
|
Revenue
|
269.4k
CAD
|
|
Operating Expenses
|
-3.3m
CAD
|
|
Operating Income
|
-3.1m
CAD
|
|
Other Expenses
|
198.2k
CAD
|
|
Net Income
|
-2.9m
CAD
|
Free Cash Flow Analysis
biOasis Technologies Inc
BTI Profitability Score
Profitability Due Diligence
biOasis Technologies Inc's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
Score
biOasis Technologies Inc's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
BTI Solvency Score
Solvency Due Diligence
biOasis Technologies Inc's solvency score is 20/100. The higher the solvency score, the more solvent the company is.
Score
biOasis Technologies Inc's solvency score is 20/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BTI Price Targets Summary
biOasis Technologies Inc
Shareholder Return
BTI Price
biOasis Technologies Inc
| Average Annual Return | -20.18% |
| Standard Deviation of Annual Returns | 51.96% |
| Max Drawdown | -98% |
| Market Capitalization | 397.1k CAD |
| Shares Outstanding | 39 707 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
biOasis Technologies Inc
Country
Industry
Market Cap
Dividend Yield
Description
biOasis Technologies, Inc. operates as a biopharmaceutical company. The company is headquartered in Richmond British Columbia, British Columbia. The company went IPO on 2007-07-24. The firm is engaged in the development of the xB3 platform, a technology for the delivery of therapeutics across the blood brain barrier (BBB) and the treatment of central nervous system (CNS) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. xB3 is based on a human transport protein found circulating at low levels in the blood. The xB3 platform has an efficacy in its ability to shuttle molecules across the blood-brain barrier and reach its targets within the brain through a process called receptor-mediated transcytosis. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.
Contact
IPO
Employees
Officers
The intrinsic value of one
BTI
stock under the Base Case scenario is
0.03
CAD.
Compared to the current market price of 0.01 CAD,
biOasis Technologies Inc
is
Undervalued by 61%.
You don't have any saved screeners yet
